Literature DB >> 12745718

Validity of a population-based cancer register in Sweden--an assessment of data reproducibility in the South-East Region Prostate Cancer Register.

Gabriel Sandblom1, Monika Dufmats, Mats Olsson, Eberhard Varenhorst.   

Abstract

BACKGROUND: With a population-based setting, high coverage and accurately recorded data, the validity of a register is guaranteed. The South-East Region Prostate Cancer relies on the National Cancer Register as a basic source of data, thereby ensuring a high coverage of the corresponding geographic area. To assess the reproducibility of the data recorded a random sample of the cases were reviewed a second time and compared to the original recording.
MATERIAL AND METHODS: The South-East Region Prostate Cancer Register was started in 1987. In addition to the basic data acquired from the Swedish National Register, it also includes tumour stage, grade, treatment and, since 1992, PSA. In the first stage of quality assessment 10 cases for each of the years 1987-1996 from Linköping University Hospital were randomly selected for two independent recodings according to the same protocol as the original registration. In the second step 10 cases each for the same years from the remaining 8 hospitals in the region were selected for a single recoding.
RESULTS: No systematic deviations were seen between the two independent recodings from Linköping, a single recoding was therefore considered sufficient for assessing the reproducibility of the data from the remaining hospitals in the region. The Kappa values for agreement between the original registration and the single recoding ranged from 0.589 to 0.869.
CONCLUSION: The population-based setting and high coverage guarantees the external validity of the register. The internal validity is ensured by the high reproducibility shown in the present study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745718     DOI: 10.1080/00365590310008839

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  14 in total

1.  Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Authors:  Daniel D Sjoberg; Andrew J Vickers; Melissa Assel; Anders Dahlin; Bing Ying Poon; David Ulmert; Hans Lilja
Journal:  Eur Urol       Date:  2018-03-05       Impact factor: 20.096

2.  Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans.

Authors:  Kristin Gunderson; Christopher Y Wang; Ruoxiang Wang
Journal:  Cancer Epidemiol       Date:  2010-12-16       Impact factor: 2.984

3.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.

Authors:  Hans Lilja; Angel M Cronin; Anders Dahlin; Jonas Manjer; Peter M Nilsson; James A Eastham; Anders S Bjartell; Peter T Scardino; David Ulmert; Andrew J Vickers
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

4.  Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Authors:  Weiqiang Li; Mridu Middha; Mesude Bicak; Daniel D Sjoberg; Emily Vertosick; Anders Dahlin; Christel Häggström; Göran Hallmans; Ann-Charlotte Rönn; Pär Stattin; Olle Melander; David Ulmert; Hans Lilja; Robert J Klein
Journal:  Eur Urol       Date:  2018-07-07       Impact factor: 20.096

5.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Authors:  Andrew J Vickers; Angel M Cronin; Thomas Björk; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  BMJ       Date:  2010-09-14

6.  Randomised prostate cancer screening trial: 20 year follow-up.

Authors:  Gabriel Sandblom; Eberhard Varenhorst; Johan Rosell; Owe Löfman; Per Carlsson
Journal:  BMJ       Date:  2011-03-31

7.  Metabolic factors associated with risk of renal cell carcinoma.

Authors:  Christel Häggström; Kilian Rapp; Tanja Stocks; Jonas Manjer; Tone Bjørge; Hanno Ulmer; Anders Engeland; Martin Almqvist; Hans Concin; Randi Selmer; Börje Ljungberg; Steinar Tretli; Gabriele Nagel; Göran Hallmans; Håkan Jonsson; Pär Stattin
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

8.  A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk.

Authors:  P Wallström; A Bjartell; B Gullberg; H Olsson; E Wirfält
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

9.  Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma.

Authors:  A Andersson; G Enblad; B Tavelin; M Björkholm; J Linderoth; I Lagerlöf; M Merup; M Sender; B Malmer
Journal:  Br J Cancer       Date:  2008-02-12       Impact factor: 7.640

10.  A population-based study of pain and quality of life during the year before death in men with prostate cancer.

Authors:  G Sandblom; P Carlsson; K Sennfält; E Varenhorst
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.